Stocks · News reference

Aligos Therapeutics Receives Upfront Payment Of $25M From Exclusive License Deal Of Pevifoscorvir Sodium In Greater China With Xiamen Amoytop; Pevifoscorvir Granted Breakthrough Therapy Designation

Jul 6, 2026, 8:07 PMBenzinga Newsdesk

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

Keep reading

BenzingaAug 12, 2026, 8:24 PMBenzinga Newsdesk
Aligos Therapeutics Initiates Dosing In Phase 1 Study Of ALG-170675, Investigational Next-Gen Antisense Oligonucleotide Being Evaluated For Functional Cure In Treatment Of Chronic HBV Infection
ALG-170675 has been optimized for both HBsAg RNA inhibition and immuno-activationSingle and multiple ascending doses plannedStudy will allow rapid advancement into participants with chronic HBV infection in Q4 2026SOUTH
ALGS
BenzingaAug 6, 2026, 5:07 PMBenzinga Newsdesk
Aligos Therapeutics shares are trading higher after the company reported better-than-expected Q2 earnings results.
ALGS
BenzingaAug 6, 2026, 12:02 PMBenzinga Newsdesk
Aligos Therapeutics Q2 EPS $(0.14) Beats $(1.07) Estimate, Sales $0.000 Miss $18.243M Estimate
Aligos Therapeutics (NASDAQ:ALGS) reported quarterly losses of $(0.14) per share which beat the analyst consensus estimate of $(1.07) by 86.92 percent. This is a 90.85 percent increase over losses of $(1.53) per share
ALGS
SEC EDGARAug 6, 2026, 12:00 PMSEC EDGAR
8-K filing — Aligos Therapeutics, Inc. (ALGS)
Filed: 2026-08-06 AccNo: 0001171843-26-005294 Size: 269 KB Item 2.02: Results of Operations and Financial Condition Item 9.01: Financial Statements and Exhibits
ALGS